"This is transformative technology that allows the recoding of life and editing"
Emmanuelle Charpentier
ERS co-founder, patent co-owner
& 2020 Nobel prize winner
ERS co-founder, patent co-owner
& 2020 Nobel prize winner
The essential intellectual property for the practice of CRISPR/Cas9
Consisting of over 85 issued patents in over 80 countries, our portfolio represents
the most foundational collection of CRISPR/Cas9
patents worldwide.